托珠单抗成功治疗检查点抑制剂诱发的关节炎:病例系列
本文报告3例在接受免疫检查点抑制剂(ICI)治疗期间出现严重多关节炎的患者,均接受托珠单抗治疗并获显著临床改善,其中1例维持了持久的抗肿瘤应答。作者认为抗IL-6受体抗体可能是治疗ICI相关关节炎的一种有效替代方案。
要点
- 托珠单抗治疗3例ICI诱发的严重多关节炎均获显著临床改善。
- 其中1例患者维持了由检查点抑制带来的持久抗肿瘤应答。
- 抗IL-6受体抗体可能替代糖皮质激素或TNFα抑制剂治疗关节炎性irAE。
核心结论
- 这3例病例提示抗IL-6受体抗体可能是治疗关节炎性免疫相关不良事件(irAE)时替代糖皮质激素或TNFα抑制剂的有效选择。
研究设计与样本
- 病例系列,报告3例在接受免疫检查点抑制剂(ICI)治疗期间出现严重多关节炎并接受托珠单抗治疗的患者。
主要发现
- 3例患者均表现出显著的临床改善。
- 1例患者维持了由检查点抑制带来的持久抗肿瘤应答。
关键数值与推荐
- 托珠单抗为抗IL-6受体抗体,是美国食品药品监督管理局(FDA)批准用于治疗类风湿关节炎和幼年特发性关节炎的生物制剂。
- 轻度irAE通常使用糖皮质激素治疗,而TNFα抑制剂保留用于难治性病例。
临床怎么用
- 对于ICI治疗期间出现严重多关节炎的患者,可考虑使用托珠单抗作为替代糖皮质激素或TNFα抑制剂的治疗选择。
- 选择托珠单抗可能避免TNFα抑制剂长期使用带来的广泛显著免疫抑制及其对ICI抗肿瘤疗效的负面影响。
局限性
- 本文为仅含3例患者的病例系列,证据级别有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with numerous cancers. However, these therapies are associated with immune-related adverse events (irAEs), which are inflammatory side effects potentially affecting any organ. Cases of ICI-induced inflammatory arthritis have also been reported. In general, mild irAEs are treated with corticosteroids, while tumour necrosis factor-α (TNFα) inhibitors are reserved for refractory cases. However, prolonged use of TNFα inhibitor (TNFαi) can induce widespread, significant immunosuppression, which can negatively impact the antitumour efficacy of ICI therapy. Therefore, in clinical scenarios where patients develop severe immunotherapy-induced irAEs, an unmet need exists for alternative therapeutic strategies that are effective and without immune dampening effects. CASE REPORTS: The anti-interleukin (IL)-6 receptor antibody, tocilizumab, is a biological agent Food and Drug Administration approved for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis. Here, we report on three patients who developed severe polyarthritis while receiving ICI therapy and were treated with tocilizumab. All three patients demonstrated significant clinical improvement; one patient maintained a durable antitumour response derived from checkpoint inhibition. CONCLUSIONS: These three cases suggest that anti-IL-6 receptor antibody may be an effective alternative to corticosteroids or TNFαi for the treatment of arthritis irAEs.
引用
- Kim ST, Tayar J, Trinh VA, et al. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis. 2017. PMID: 28830882. doi:10.1136/annrheumdis-2017-211560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。